Key result
D-penicillamine administration in 15 patients with rheumatoid arthritis resulted in clinical improvement in 66.7% of patients and a fall in rheumatoid factor titer in all patients.
Why the study?
Does D-penicillamine improve clinical symptoms and laboratory markers in patients with rheumatoid arthritis?
Does D-penicillamine improve clinical symptoms and laboratory markers in patients with rheumatoid arthritis?
D-penicillamine administration in rheumatoid arthritis patients is associated with decreased rheumatoid factor titers and clinical improvement.
Answers are grounded in this paper and cite their sources.
May support D-penicillamine in rheumatoid arthritis; leaves open confirmation in randomized trials.
D‐penicillamine was administered to 15 patients with rheumatoid arthritis. A fall in the titer of rheumatoid factor was demonstrated in all patients. The sedimentation rate decreased in most patients. There was no consistent alteration in immunoglobulins A, G or M or in lymphocyte transformation attributable to penicillamine. Ceruloplasmin serum levels were lowered significantly in 7 patients. Clinical improvement in the arthritis resulted in 10 patients.
No takes yet. Share an insight, caveat, or question.
Zuckner et al. (1970) studied rheumatoid arthritis (n=15). D-penicillamine was evaluated on Clinical improvement in the arthritis. D-penicillamine administration in 15 patients with rheumatoid arthritis resulted in clinical improvement in 66.7% of patients and a fall in rheumatoid factor titer in all patients.
Synapse has enriched 10 related papers. Consider them for comparative context: